阿斯利康完成13亿美元收购CinCor的高血压药物三期试验-动脉网

AstraZeneca Completes Phase 3 Trial for Hypertension Drug Acquired in $1.3 Billion CinCor Deal

GeneOnline 等信源发布 2025-07-14 22:07



可切换为仅中文







by Mark Chiang

马克·蒋

Share To

分享到

AstraZeneca has announced that its experimental drug for uncontrolled or treatment-resistant hypertension has successfully completed a phase 3 clinical trial. The development comes two years after the pharmaceutical company acquired CinCor Pharma in a $1.3 billion deal, with the drug being the primary asset of that acquisition.

阿斯利康宣布，其用于治疗不受控制或治疗抵抗性高血压的实验性药物已成功完成 3 期临床试验。这一进展是在这家制药公司以 13 亿美元收购 CinCor Pharma 两年后取得的，而这款药物正是该收购案中的主要资产。

AstraZeneca is now preparing to file for regulatory approval based on the trial results..

阿斯利康现在正准备根据试验结果申请监管批准。

The phase 3 trial marks a significant milestone for the drug, which aims to address cases of high blood pressure that do not respond adequately to existing treatments. AstraZeneca’s acquisition of CinCor Pharma in 2023 was largely driven by this potential therapy, underscoring its strategic importance within the company’s portfolio.

这项第三阶段试验标志着该药物的一个重要里程碑，该药物旨在解决对现有治疗反应不佳的高血压病例。阿斯利康2023年收购CinCor Pharma很大程度上是受到这一潜在疗法的推动，凸显了其在公司产品组合中的战略重要性。

Details regarding the specific outcomes of the trial have not been disclosed, but clearing this stage positions AstraZeneca closer to bringing the medication to market pending regulatory review..

关于试验的具体结果尚未披露，但通过这一阶段使阿斯利康在等待监管审查后更接近将这种药物推向市场。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: July 14, 2025

日期：2025年7月14日

Navigating Drug Patents: Pharmaceutical Companies Strategize in a Landscape Where Over 300 Drugs Lose Exclusivity This Decade

应对药物专利：制药公司在本十年超过300种药物失去独占权的格局中制定策略

Reshema Kemps-Polanco of Novartis US Named 2025 HBA Woman of the Year

诺华美国的雷舍玛·肯普斯-波兰科被评为2025年HBA年度女性。

Study Links Aphantasia to Altered Brain Connectivity Using 7T fMRI Technology